Liminatus Pharma, Inc. (LIMN)

NASDAQ: LIMN · Real-Time Price · USD
7.11
-0.09 (-1.25%)
Jul 11, 2025, 9:57 AM - Market open
-1.25%
Market Cap 184.96M
Revenue (ttm) n/a
Net Income (ttm) -3.55M
Shares Out 26.01M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,241
Open 6.99
Previous Close 7.20
Day's Range 6.85 - 7.20
52-Week Range 4.40 - 33.66
Beta 0.57
Analysts n/a
Price Target n/a
Earnings Date n/a

About LIMN

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country United States
Stock Exchange NASDAQ
Ticker Symbol LIMN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.